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Abstract 
Alginate hydrogel particles are promising delivery systems for protein encapsulation and controlled 
release because of their excellent biocompatibility, biodegradability, and mild gelation process. In 
this study, a facile microfluidic approach is developed for making uniform core-shell hydrogel 
microparticles. To address the challenge of protein retention within the alginate gel matrix, 
poly(ethyleneimine) (PEI)- and chitosan-coated alginate microparticles were fabricated 
demonstrating improved protein retention as well as controlled release. Furthermore, a model protein 
ovalbumin was loaded along with delta inulin microparticulate adjuvant into the water-core of the 
alginate microparticles. Compared to those microparticles with only antigen loaded, the antigen + 
adjuvant loaded microparticles showed a delayed and sustained release of antigen. This microfluidic 
approach provides a convenient method for making well-controlled alginate microgel particles with 
uniform size and controlled properties, and demonstrates the ability to tune the release profiles of 
proteins by engineering microparticle structure and properties. 
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Introduction 
Bioactive agents have been widely used in many industries such as pharmaceutical, food industries. 
For example, biologic drugs including peptides, proteins, antibodies, cytokines have been the driving 
force in pharmaceutical companies in recent years [1]. More than half of the drugs in development 
are biologics with the number increasing exponentially from 900 in 2013 to 2,700 in mid-2017 [1]. 
However, each biologic drug has its own unique properties that affects their stability and potential 
applications. It is important to develop improved delivery strategies to facilitate biologics delivery to 
the target site at a therapeutic level for the required period of time. 
A wide variety of delivery systems have been developed to encapsulate biologic drugs and control 
their release including polymer particles, inorganic particles, and gel particles [2]. Several polymers 
such as poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA) have been approved for food 
and pharmaceutical applications because of their excellent biocompatibility and degradability [3-5]. 
Polymeric micro/nanoparticles are mainly generated by double emulsion approaches in combination 
with solvent evaporation or spray drying [3, 4]. The harsh conditions and toxic solvents involved in 
the formation of solid polymer particles remain a concern for their pharmaceutical applications. 
Inorganic particles such as silica have also been widely investigated for protein encapsulation and 
delivery [6], but their biocompatibility and safety limit their practical applications in pharmaceuticals. 
Natural polysaccharides, such as chitosan, alginate, or hyaluronic acid have excellent biocompatiblity 
and biodegradability, and are safe for food and pharmaceutical applications [7-9]. For example, 
alginate has been widely used for protein encapsulation and drug delivery. In addition to its good 
biocompatibility, one of the other advantages is that alginate can crosslink with polyvalent metal 
cations such as divalent cations Mg
2+
, Ca
2+
, and Ba
2+
 under mild conditions. Several approaches have 
been developed for producing alginate gel particles based on a droplet-to-particle strategy, such as 
commercially-available droplet generators  [10], simple syringe set-ups [11], and emulsion-
templating methods [12]. However, these methods lack control of particle size and size distribution. 
The advent of microfluidic technology offers a new approach for making uniform droplets with 
controlled size and size distribution for various applications, such as drug encapsulation [13, 14], 
tissue engineering [15, 16], food industry [17], and chemical processing [18, 19]. Various 
microfluidic approaches have been developed for generating alginate particles. In these devices, 
alginate particles are gelated by either external gelation or internal gelation [20]. Internal gelation can 
maintain the spherical structure of alginate particles but produce partially and incomplete crosslinked 
particles with weak stiffness. As the gelation progress is dependent on the diffusion of calcium ions 
from the inner core to the particle surface [21], the internal gelation method takes a longer time to 
make fully crosslinked alginate particles. To solve this problem, these particles can be collected in a 
  
calcium bath to further strengthen the crosslinking of alginate [22]. Compared to internal gelation, 
external gelation is more rapid. Typically, alginate droplets are formed inside microfluidic channels 
and then collected in a container containing calcium ions. Once the alginate droplets come in contact 
with Ca ions, the gelation process is initiated, and further gelation inside the alginate droplet is 
controlled by the diffusion of calcium ions into the droplets [20]. Alginate particles produced by this 
approach are normally stiffer than particles formed using internal gelation. External gelation faces 
some problems because of the rapid gelation progress, and the rapid crosslinking of alginate with 
calcium ion results in difficulties in forming spherical particles, such as pearl-like strings [23]. 
Besides, after the outer layer of the alginate droplets is gelated, it is difficult for calcium ions to 
diffuse into the inner core. As a result, the inner core is not fully cross-linked [24]. Furthermore, 
alginate hydrogel microparticles have pores of 5-200 nm, which is bigger than many biomolecules, 
resulting in low protein retention (10% or less) [25]. Therefore, it is of importance to fabricate 
alginate microparticles with well controlled size and shape, and good retention of biomolecules. 
In this work, we developed a microfluidic approach for making uniform core-shell alginate microgel 
particles with uniform size. To retain the spherical shape of the microparticles, we combined the in 
situ and ex situ cross-linking strategies. Firstly, a model protein was encapsulated inside the microgel 
particles under different conditions. Two different approaches were adopted to improve the retention 
of the biomolecules. One was to coat the alginate microparticles using oppositely charged polymers 
including poly(ethyleneimine) and chitosan. Another was to add small particles inside the water core 
as pore capping agents to block the pores of the alginate hydrogel network, thus preventing the 
escape of the biomolecules. The effect of different coatings and particle capping on the protein 
encapsulation and their controlled release was also investigated.  
Experimental 
Materials 
Medium viscosity sodium alginate (> 200 mPas) where minimum 60% of the monomer units are 
guluronate was purchased from Novamatrix, USA. Mineral oil, and poly(ethyleneimine) (PEI) 50% 
(w/v) in H2O solution, and ovalbumin from chicken egg white (>98%) were purchased from Sigma-
Aldrich, USA. Delta inulin microparticles were provided by Vaxine Pty Ltd, Adelaide, Australia. 
Water with >18.2 MΩ cm resistivity was obtained from a Milli-Q system. Other chemicals of 
analytical grade including (Ethylenedinitrilo)tetraacetic acid (EDTA, >99% purity), calcium 
carbonate (CaCO3, >99%), calcium chloride (CaCl2, >97%),  were purchased from either Sigma-
Aldrich or Merck and used as received unless otherwise stated.  
 
  
Preparation of microfluidic flow-focusing devices 
The microfluidic device was designed and fabricated by standard photolithography and soft 
lithography [26, 27]. SU-8 2050 was spin-coated on a silicon wafer and exposed to UV for 30 
seconds (Neutronix Quintell 7500 UV mask aligner). The wafer was then developed by SU-8 
developer. After baking at 150℃ for 20 minutes, the wafer was submerged by PDMS 
(Polydimethylsiloxane) and cured for 30 minutes to replicate the patterns of the microchannels on a 
PDMS stamp. The stamp was then peeled off and bound onto a glass substrate pre-coated with a thin 
layer of PDMS. For better combination, both PDMS stamp and glass substrate were treated with 
oxygen plasma for 30 seconds before binding. The PDMS device was then baked at 80℃ for 2 days 
to get a hydrophobic interior. The height and width of the microchannel are 100 μm. 
Preparation of antigen loaded microparticles 
The microfluidic device was designed to have four inlets and one outlet (Figure 1). Dextran or 
protein aqueous solutions were introduced from inlet 1. 2% (wt%) alginate solution containing 200 
mM CaCO3 was pumped through inlet 2. The CaCO3+alginate solution was prepared by mixing 400 
mM CaCO3 with 4% (wt %) alginate solution at 1:1 volume ratio and stirred overnight at room 
temperature. Mineral oil with 3% (wt %) Span 80 was used as the oil phase A and flowed through the 
inlet 3. Span 80 was used as a surfactant to prevent droplet coalescence during droplet formation. 
Mineral oil with 3% (wt %) Span 80 and 0.2% (v/v) acetic acid was used as the second oil phase (oil 
phase B) and introduced from the inlet 4. Acetic acid was used to trigger the release of calcium ions 
from CaCO3-alginate complex.  
The solutions were pumped into the microfluidic device in the following order: two oil phases were 
pumped into the device at the same time before starting the flows of CaCO3-alginate solution and 
protein aqueous solution. The flow rates for both oil phase A and B from inlet 2 and 1 were 10 
μL/min and 14 μL/min, respectively. After the device was filled with the oil phase, the protein 
aqueous solution and CaCO3-alginate solution were started at the flow rates of 1 and 0.5 μL/min, 
respectively. The pre cross-linked alginate microparticles were formed in the microfluidic device, 
travelled along a collection tubing and were dropped into a gelation bath containing 100 μM CaCl2 
solution, or 0.3 wt % PEI and 100 μM CaCl2 solution, or 100 μM CaCl2 and 0.1% (w/v) chitosan in 1% 
(v/v) acetic acid. Then the alginate gel microparticles were centrifuged at 2000 rpm for 20 minutes to 
allow the microgel particles settle down from the floating oil phase to the water phase, and the 
solution was transferred into a glass column,  where the microparticles descended to the bottom by 
gravity and were collected to a tube, the layer of oil phase were removed. The encapsulation 
efficiency was calculated using the following equation: 
  
                        
  
                                         
                                                                               
 
      
The amount of OVA in the microgel particles was determined by dissolving all the particles using 
EDTA. 
In vitro release  
For release studies, the antigen-loaded gel microparticles were resuspended in Milli-Q water for 
release study. The supernatant was collected from 5 mL suspension at different time points, and 
replaced with fresh water or buffer at different pH depending on what release buffer was used. The 
concentration of antigen released to buffer was measured by Ultraviolet-visible spectroscopy (UV-
2450, Shimadzu) at the antigen excitation wavelength of 280 nm. The release process was kept at 
4°C until the end of the release experiments. Then the beads were fully dissolved by adding EDTA. 
All experiments were conducted in triplicate. 
Characterization of microparticles 
The wet microparticles were observed with an optical light microscope (Nikon Eclipse TS100). The 
size was estimated on counting 200 microparticles with the optical microscope. A Confocal Laser 
Scanning Microscopy CLSM (Zeiss 710, Jena, Germany) was used to observe dye labelled core shell 
alginate microparticles.  
 
Results and Discussions 
A four-inlet microfluidic device (Figure 1) was designed [26] and used for making water-core 
alginate-shell microparticles for antigen encapsulation and controlled release. An antigen aqueous 
solution is introduced from the inlet 4 and co-flows with 2% (w/v) alginate solution containing 200 
mM CaCO3 from the inlet 3. This co-flow forms a core-shell stream and is sheared off by the 
continuous phase mineral oil containing 3% Span 80 (w/w) from the inlet 2. Antigen-water core 
alginate shell microparticles are formed at the second junction. Mineral oil with 3% Span 80 and 0.2% 
(v/v) acetic acid is introduced from the inlet 1 to release the calcium ions from CaCO3 in the alginate 
shell, thus initiating the crosslinking of the alginate shell in the microchannel (Figure 1). Then the 
crosslinked antigen-core alginate-shell microparticles are collected in a collecting bath containing 
0.27 M CaCl2 aqueous solution to complete the crosslinking (Figure 1). Monodisperse microgel 
particles were formed (Figure 2A) in the oil phase showing a high contrast. But when they were 
transferred to an aqueous collecting bath, the contrast between microgels and the aqueous phase was 
  
decreased because both were aqueous, while the microgel particles remained stable, spherical and 
uniform in size (Figure 2B), which is in contrast to many alginate microparticles that show 
mushroom-like or pear like morphology. This is mainly due to the slow gelation process within the 
microfluidic channel in combination with the subsequent bulk crosslinking. It has been shown that 
spherical alginate particles could have a more sustained release. 
  
Figure 1.  
 
Figure 1 Formation of uniform water-core alginate-shell microdroplets. a) Four-inlet microfluidic 
device for making core-shell alginate microparticles b) Schematic illustration of the core-shell 
structure.  Inlet 1: Mineral oil with 3 wt% Span 80 and 0.2% (v/v) acetic acid; Inlet 2: Mineral oil 
with 3 wt% Span 80; Inlet 3: 2% (w/v) alginate solution containing 200 mM CaCO3; Inlet 4: an 
antigen or protein aqueous solution. 
 
Figure 2 Microscope images of core-shell alginate microdroplets. a) Collected in oil phase; b) 
Transfer to water phase. The scale bar is 100 µm. 
PEI-coated alginate microparticles for protein encapsulation 
  
Before encapsulating protein molecules, 40 KDa FITC-dextran was used as a model molecule as it is 
easy to observe under confocal microscopy. FITC-dextran was introduced from the inlet 4 and co-
flowed with an alginate solution. After the formation of core-shell alginate microgel particles in the 
microfluidic device, the particles were collected in a CaCl2 crosslinking bath. However, the 
fluorescence intensity was very weak (Figure 3A) due to the quick release of dextran from the gel 
matrix to the external aqueous phase. It has been reported that the pores within alginate microgel 
particles range from 5-200 nm, which is much bigger than the size of 40 KDa FITC-dextran. 
Therefore, the retainment of dextran is very low, which is similar to others’ work showing that only 
10% of the protein can be retained in the microgel matrix [25]. 
Two different approaches have been proposed to prevent the quick diffusion of biomolecules with 
sizes smaller than the pores of alginate hydrogel. One is to increase the crosslinking degree of 
alginate, so smaller pores can be formed. Alternatively, alginate microparticles can be covered with 
polymers, and act as a diffusion barrier thus stopping the escape of the encapsulated biomolecules. 
Because of alginate’s negative charge property, positively charged polymers are able to quickly 
adsorb to the surface of alginate microparticles through electrostatic interaction. In this study, a 
highly positively charged polymer, poly(ethyleneimine) (PEI) at a concentration of 0.5 wt%, was 
used to prevent the premature release of the encapsulated dextran. Figure 3b shows that the 
fluorescence intensity is much higher than that without PEI indicating that the coverage of PEI on the 
microgel particles does improve the retention of dextran within the particles. Figure 3c shows the 
crumbled surface of these microgel particles. This is mainly due to the quick adsorption of highly 
positively charged PEI on the negatively charged alginate particle surface. To improve the surface 
morphology of the PEI-coated microgel particles, the concentration of the PEI could be reduced to 
slow down the adsorption rate, thus a smooth particle surface. 
 
Figure 3. Encapsulation of Dextran in alginate microgel particles. (a) Fluorescence image of microgel 
particles after collected in a crosslinking CaCl2 bath; (b) Fluorescence image and (c) optimal image 
of microgel particles after collection in 0.5 wt% PEI. 
  
Next, OVA, a 42.7 kDa protein having a similar size to the 40 KDa FITC-dextran, was used as a 
model protein or antigen for encapsulation. Similarly, water containing dye-labelled OVA was 
introduced from the inlet 4. After the OVA encapsulated microgel particles were collected in the 
crosslinking bath containing 0.3 wt % PEI and 100 μM CaCl2 solution. It can be seen that the core-
shell alginate microparticles showed very strong fluorescence indicating the successful encapsulation 
of OVA in the microparticles (Figure 4a). The OVA-loaded core-shell alginate mciroparticles were 
collected and then dispersed in water and studied its release over time. The release of OVA was 
measured by UV-Vis at 280 nm. After 140 hours, the alginate particles were dissolved with EDTA to 
quantify the total amount of encapsulated protein. The protein encapsulation efficiency of this PEI-
coated alginate microparticles was 88%, which is higher than the highest efficiency (58.6%) in others’ 
reported work [25]. Figure 3d shows the release profile of OVA from the microparticles (Figure 4b). 
It was released gradually over 120 hours (5 days), demonstrating the slow release of OVA from the 
PEI coated core-shell alginate microparticles. 27% of the protein was released in the first 4 hours, 
then 62% at 24 h. It took 5 days for the protein to be completely released. The release of OVA has a 
good correlation with the square root of time, indicating the release is dependent on Fickian diffusion. 
 
 
Figure 4 Encapsulation of dye-labelled OVA in PEI coated core-shell alginate microparticles. (a). 
dye-labelled OVA encapsulated in PEI coated microgel particles; (b). Sustained release of OVA in 
the PEI coated microgel particles. The solid line shows the experimental results, and the dotted line is 
a theoretical fitting using a function of the square root of time.  
pH responsive release of proteins 
In addition to coating the core-shell alginate microparticles with positively charged PEI, we explored 
an alternative polymer, chitosan, to coat the particles. One of the advantage of making chitosan 
coated core-shell alginate microparticles is its mucoadhesive property. Chitosan is insoluble at 
neutral pH and only soluble in acid conditions. A crosslinking bath containing 100 μM CaCl2 and 0.1% 
  
(w/v) chitosan in 1% (v/v) acetic acid was prepared for collecting and crosslinking the alginate 
microparticles. Very uniform chitosan-coated alginate microparticles were formed (Figure 5a). The 
microparticles show very spherical shape and bright fluorescence intensity. Figure 5b illustrates the 
fluorescence intensity distribution over the centre of the microparticles with three peaks appearing at 
the edges and centre. This non-uniform distribution is probably due to the heterogonous diffusion 
rates of OVA in the water core and alginate shell. The protein encapsulation efficiency of this 
chitosan-coated alginate microparticles is 80% and slightly lower than that of the PEI-coated alginate 
microparticles (88%), mainly due to the less strong electrostatic interaction between alginate and 
chitosan in acid conditions.  
Polymer-coated alginate microparticles are promising oral delivery vehicles for proteins or biological 
drugs, so they have to go through the gastrointestinal tract to the small intestine. Therefore, the 
chitosan-coated alginate microparticles were investigated firstly for release at pH 3 then at pH 7. For 
the first 5 days at pH 3, the release of OVA was minimum, which could be attributed to the barrier 
effect of chitosan as well as the smaller pore sizes of the alginate network at lower pH. On the other 
hand, the electrostatic interaction between OVA and alginate became stronger because of the more 
positive charges of OVA at lower pH. In contrast, when the pH was increased to 7, the particles 
displayed an accelerated OVA release (Figure 5c) due to the enlarged pores of the gel structure at 
neutral pH as well as the weakened chitosan strength at acid pH. Within two days, 100% of OVA 
was released. This pH-responsive release of proteins could have potential in various applications. 
Moreover, the pH-responsive properties can be tuned by integrating different gel materials and 
polymer coating layer, thus realizing the precisely controlled protein release to suit different 
conditions. 
              
  
 
Figure 5 OVA encapsulated core-shell alginate microparticles coated with chitosan. (a) Confocal 
image of fluorescent OVA encapsulated alginate microparticles; (b) Fluorescent intensity distribution 
along the diameters of two different alginate microparticles (shown in green and red dot lines); (c) 
pH triggered release of OVA from the microparticles. 
Alternative way to control drug release 
Two different strategies can be utilized to retain proteins within the alginate microparticles. As we 
discussed above, covering the microparticles with a layer of polymer would serve the purpose (Figure 
6a).  Additionally, the interface between the water core and alginate shell can be further engineered 
to act another barrier for controlling protein encapsulation and controlled release. Therefore, we 
tested delta-inulin microparticles as pore blockers or caps inside the water core. Delta-inulin (DI, 
Advax
TM
) is a new vaccine adjuvant with superior adjuvant potency [27, 28], which has been 
demonstrated in various animal models, such as HIV [29], human seasonal influenza [30] and has 
also been tested in human clinical trials of influenza vaccine [31], hepatitis B vaccine [32], and bee 
venom-based immunotherapy [33]. Briefly, water or buffer solution containing delta inulin particles 
and OVA was introduced from the microfluidic device, so the particles and protein were 
encapsulated inside the water core. As the inulin particles have a diameter of around 2 μm, which is 
large enough to block the pores of the alginate network, thus preventing the escape of the protein. 
  
The microparticles were then further coated with PEI. Figure 6 shows the OVA and delta-inulin 
encapsulated microparticles. With the delta-inulin particles, the encapsulation efficiency increased to 
91%, which is slightly higher than for alginate microparticles only coated with PEI (88%). Figure 6d 
compares the release of protein from the OVA-encapsulated microparticles and OVA-delta inulin 
encapsulated microparticles. With the encapsulation of delta-inulin in the core, the release of OVA 
was significantly slowed down. After 7 days, only around 20% of OVA was released. Then the 
alginate microparticles were dissolved in EDTA to release all the OVA. 
 
  
Figure 6 Core-shell microgel particle for encapsulation and controlled release. (a) Two different 
strategies for improving protein retainment and their controlled release. (b) Inulin microparticles; 
(c) OVA and delta inulin encapsulated alginate microparticles; (d) Release of OVA from OVA 
encapsulated microparticles and OVA + delta inulin encapsulated microparticles 
 
Conclusions 
Microgel particles have been widely used for protein encapsulation, but how to make uniform 
particles with well controlled spherical morphology and high protein encapsulation efficiency 
remains a challenge. In this work, we developed a simple microfluidic approach for making uniform 
core-shell alginate hydrogel microparticles for protein encapsulation and controlled release. To 
  
control the morphology of the alginate microparticles, we combined the in situ and ex situ 
crosslinking strategies, so the gelation process started within the microchannel and completed in the 
bulk gelation bath, ensuring the microparticles’ spherical structure. To improve the protein’s 
retention efficiency, two different approaches were developed and compared. One was to coat the 
microparticles with a layer of oppositely charged polymer, which can act as a diffusion barrier. 
Another was to encapsulate proteins along with delta inulin polysaccharide microparticles within the 
water core, so the microparticles can work as pore caps thus preventing the escape of protein. 
Combining the two strategies, the PEI coated OVA-delta inulin encapsulated alginate microparticles 
can achieve up to 90% protein encapsulation efficiency. Furthermore, two different polymers (PEI 
and chitosan) were successfully applied to make polymer-coated alginate microparticles, allowing 
either sustained release or pH-responsive release of loaded protein. The incorporation of delta inulin 
microparticles had the further advantage that it further slow down protein release. This microfluidic 
approach provides a precise control of the formation of alginate microparticles with core-shell 
structures for protein encapsulation and controlled release. The fabricated microparticles have great 
potential for vaccine delivery. In our future work, antigens will be loaded into the microparticles and 
used for sustained release vaccines. 
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